


# **ASAHI INTECC CO., LTD.**

## **Company Profile**



**August, 2026**

**(Securities code:7747 Prime of Tokyo Stock Exchange and Premier of Nagoya Stock Exchange)**

# Company Profile

| Company Name                  | ASAHI INTECC CO., LTD.                                                                                                                                                    |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Head Office                   | 3-100 Akatsuki-cho, Seto-shi, Aichi, Japan                                                                                                                                |
| Representative                | Masahiko Miyata, Representative Director & Chairman<br>Kenji Miyata, President & CEO                                                                                      |
| Date of Establishment         | July 8, 1976 (Currently, the 51st term)                                                                                                                                   |
| Business Operations           | Development, manufacturing and sale of medical devices<br>Development, manufacturing and sale of ultra-fine stainless steel wire ropes, terminal processed products, etc. |
| Consolidated net sales        | 145,419 Mil.Yen (FYE June 2026)                                                                                                                                           |
| Consolidated operating profit | 45,218 Mil. Yen (FYE June 2026)                                                                                                                                           |
| Capital                       | 18,860 Mil. Yen (FYE June 2026)                                                                                                                                           |
| Number of Employees           | 1,285 (Asahi Intecc only) 10,177 (Total) (as of end of June 2026)                                                                                                         |
| Affiliated Companies          | 20 Consolidated subsidiaries, 5 Non-consolidated subsidiaries                                                                                                             |
| R&D bases                     | Japan, Thailand, US                                                                                                                                                       |
| Manufacturing bases           | Thailand, Vietnam, Philippines, China *                                                                                                                                   |
| Sales bases                   | Japan, US, Netherlands, France, Germany, Italy, Russia, China, South Korea, Taiwan, Hong Kong, Singapore, Thailand, India, UAE, Brazil, Saudi Arabia                      |
| Stock exchange listing        | Tokyo Stock Exchange Prime Market, Nagoya Stock Exchange Premier Market (Securities code 7747)                                                                            |

# Global Network – R&D/Production (Coexistence of Japan & Overseas)



**GLOBAL HEADQUARTERS  
AND R&D CENTER  
(Product R&D)**



**THAILAND :  
ASAHI INTECC THAILAND CO., LTD.**



**China:  
Asahi Inda Medical Equipment  
(Nanning) Co., Ltd.**

※Scheduled to begin operations around  
December 2030.



**PHILIPPINES :  
TOYOFLEX CEBU CORPORATION**



**VIETNAM :  
ASAHI INTECC HANOI CO., LTD.**

**Production 3 Bases  
1 Base in Preparation**


**【OVERSEAS】  
Production bases**

**【JAPAN】  
R&D/Prototype**


Japan conducts R&D and prototyping; mass production takes place in overseas factories.



# Sales Bases



# R&D Bases



# Business Fields and Divisions

## ■ FYE June 2026

Revenue 145,419Mill. Yen

Operating income 45,218Mill. Yen

## Medical Division ( Medical Brand / Medical OEM )



## Medical Field (approx. 95%)



## Industrial Field (approx. 5%)




## Device Division

( Medical Components / Industrial Components )

# Expanding from the Industrial Components Field to the Medical Device Field

Leveraging the ultra-fine stainless steel wire rope technology cultivated in the industrial components field, we have entered the medical device field.  
In particular, the overseas market for the medical division has grown significantly.





# Business Overview and Main Product Groups

Starting from the manufacturing of wire ropes for industrial machine, expanding business into the medical device field (Access devices)



**Industrial components**



Wire

Synchromesh rope

<< Markets Where Used >>



Sports


Home Appliances

OA Equipment

**Medical components**



Wire Rope / Tubes  
(Materials for Endoscopic Treatment Devices)



ACT ONE

**Own Brand Products / OEM Supply**

**Therapeutic Access Devices**



PCI Guide Wires

Main products  
account for about 50% of sales



PCI Balloon Catheters


**OEM Supply**



PCI Guiding Catheters



Penetration catheters







# Main Products of Medical Device

## Guide Wires and Catheters for Treatment





- Cardiovascular
  - **PCI Guide Wires**
  - PCI Guiding Catheters
  - PCI Balloon Catheters
  - Penetration Catheters
- Peripheral Vascular, Abdominal Vascular, Cerebrovascular Systems
  - Peripheral Guide Wires
  - IVR Guide Wires
  - Cerebrovascular System Guide Wires

## Guide Wires and Catheters for Examination

- Guide Wires for Angiography
- Catheters for Angiography

## OEM supplies

- Products other than Cardiovascular Catheters




Our main product at **48.4%** (FYE June 2026) of Revenue

# PCI (Percutaneous Coronary Intervention)-1

- Therapy for coronary artery disorder (angina, myocardial infarction )
- Recover the blood flow after dilatation of stenosed lesion
- Treatment through femoral or radial artery without laparotomy and thoracotomy to minimize the mental and physical burden on patients.

## Surgical Therapy

### Bypass Operation



## Interventional Therapy

### Minimally Invasive Treatment (PCI Treatment )




# PCI (Percutaneous Coronary Intervention)-2

**For PCI treatment to be successful, the PCI guidewire must reach the affected area**


## ① PCI GW Advancement

Small size tube called PCI Guiding Catheter inserted in blood vessel. Advance PCI GW inside of this tube.




## ② PCI Balloon Catheter Tracking

Along with PCI GW, PCI Balloon Catheter trucked over PCI GW to the point of the narrowed portion of vessel.





## ③ PCI Balloon Catheter dilatation

Dilate Balloon, then enlarge the blood vessel.



## ④ PCI Balloon Catheter pulled out

After Narrow portion enlarged then blood flow to recover.




# PCI (Percutaneous Coronary Intervention)-3

## Comparatively easy lesions




## Lesions with high difficulty





# Market Trend: Market Share of Our Main Product PCI GW [FYE June 2026]

(Our estimate)



**Continue to strive to expand market share in all regions**

# Technological Advantages: 4 Core Technologies

High transmissibility of rotation(Torquability)



Tip flexibility(Safe operation)



Doctors manipulate the wire and try to transfer the feeling of finger tip to the distal end of wire.

## Source of competitiveness: 4 core technologies

Control of hardness and diameter



Wire drawing technology

Wire forming technology

Micron-level molding



Rotation following capacity



Torque technology

Resin coating technology

Ultra-thin film coating




Integrated production system  
handling materials down to  
the finished products

# Our Company's Flagship CTO Treatment: Implementation of PCI Treatment in CTO Cases

## ■ What is CTO ? ( Chronic Total Occlusion )

- A disease of hard calcification
- Completely clogged up blood vessel



## 【 Level of heart disease 】

Healthy person → Risk holder

Lifestyle-related diseases

Cardiovascular occlusion

**CTO**

(Chronic Total Occlusion)

Latent patient

**Previously realm of surgical operations**


**In the era when the Japanese market depended on imports for PCI GW, Japanese KOL requested major manufacturers to make a wire for CTO PCI but were turned down.**

※KOL(Key Opinion Leader)・・・A physician with influence over the direction of PCI.

**PCI GW for CTO Procedures (1995)**


**Aggressive expansion of CTO cases via minimally invasive procedures**

Our Strength:  
Competitive Power in Medical Devices” Based on “High Technology  
for Raw Material





# Our Strength: Merits of Segmental Structure (fusion/combination/circulation)



# Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

**Asahi Intecc Co., Ltd.**  
**corporate strategic office**

TEL 0561-56-1851

URL <https://www.asahi-intecc.co.jp/en>